Taipei, Taiwan

Yu Lung Chang

This inventor holds 22 USPTO granted patents, primarily in Radiotracer Development. Top assignees: Institute of Nuclear Energy Research, Entire Technology Co., Ltd., Inotera Memories, Inc.. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yu Lung Chang. Retrieved from https://idiyas.com/inventor/yu-lung-chang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 40.9

Average Co-Inventor Count = 3.3

ph-index = 2

Forward Citations = 11(Granted Patents)


Location History:

  • Taoyuan County, TW (2011 - 2017)
  • Taipei, TW (2012 - 2018)
  • Taoyuan, TW (2017 - 2022)

Company Filing History:


Years Active: 2011-2026

Loading Chart...
Areas of Expertise:
Contrast Agent
Radiotracer
Semiconductor Device
Benzodiazepine Derivative
Flame Retarding Composite
Diagnostic Imaging
Therapeutic Agent
Organoboron Derivative
Multiplex Slide Plate
Bifunctional Compound
Dopamine Imaging
Manufacturing Method
22 patents (USPTO):Explore Patents

Title: Yu Lung Chang - Innovator in Nuclear Medicine and Imaging Technologies

Introduction

Yu Lung Chang is a prominent inventor based in Taipei, Taiwan, recognized for his significant contributions to the fields of nuclear medicine and imaging technologies. With an impressive portfolio of 21 patents, Chang has developed groundbreaking methods that enhance diagnostic techniques for various health conditions, including neurological disorders.

Latest Patents

Among his latest innovations is a patented method for preparing a non-radioactive standard β-CFT. This invention details a streamlined process utilizing cocaine hydrochloride as the starting material, undergoing hydrolysis, dehydration, esterification, and bonding reactions. This method is notable for its fewer operational steps, ease of use, and a remarkable product purity of 97.97%. By promoting advancements in positron imaging, this invention holds the potential to significantly aid in the diagnosis of Parkinson's disease.

Another notable patent is for the preparation of S-Bz-MAG3, a precursor of contrast media. This process involves a thiol protection reaction using thioglycolic acid and benzoyl chloride, followed by the formation of ester compounds through the reaction of N,N'-dicyclohexylcarbodiimide and N-hydroxysuccinimide. The resulting ester compounds are then combined with triglycine in an amide bonding reaction, producing a bifunctional chelator that can effectively bridge with isotopes like 99mTc and 186/188Re. This innovation not only simplifies synthesis but also increases productivity, making it valuable for nuclear medicine imaging and tumor radiotherapy.

Career Highlights

Yu Lung Chang has been associated with several prestigious institutions, including the Atomic Energy Council and the Institute of Nuclear Energy Research. His work in these organizations has been instrumental in pushing the boundaries of innovative research and development in nuclear technology and its applications.

Collaborations

During his career, Chang has worked alongside notable colleagues such as Cheng-Fang Hsu and Show-Wen Liu. Their collaboration has contributed to the advancement of technologies that bridge the gap between chemical processes and medical applications, enhancing the effectiveness of diagnostics and treatment options in the medical field.

Conclusion

Yu Lung Chang stands out as a visionary inventor whose work has substantially impacted nuclear medicine and imaging technology. His innovative patents not only demonstrate his expertise and dedication but also promise to improve diagnostic capabilities for diseases like Parkinson's, paving the way for future advancements in medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…